Pharmacological Interventions for Glucocorticoid-Induced Osteoporosis: An Umbrella Review

Horm Metab Res 2023; 55: 511-519 DOI: 10.1055/a-2112-1596There is still a lack of high-quality evidence-based studies on the efficacy of
drug treatment for glucocorticoid-induced osteoporosis (GIOP). The purpose of
this umbrella review is to comprehensively evaluate the existing evidence to
determine the efficacy and safety of pharmacological interventions for GIOP. We
searched PubMed, Embase, and the Cochrane Library for systematic reviews
and/or meta-analyses (SRs) of randomized controlled trials (RCTs) aimed
at evaluating drug therapy for GIOP. Both the methodological quality and the
strength of recommendation of the endpoints included in the SRs were evaluated
by using the AMSTAR-2 tool and GRADE system, respectively. Six SRs involving
7225 GIOP patients in 59 RCTs were included in this umbrella review. The results
of the methodological quality evaluation showed that 2 high-quality, 2
low-quality and 2 critically low-quality SRs were included. The GRADE evaluation
results showed that the quality of evidence and the strength of recommendation
of 46 outcome indicators were evaluated in the umbrella review; there were 3
with high-level evidence, 20 with moderate-level evidence, 15 with low-level
evidence, and 8 with very low-level evidence. Moderate- to high-level evidence
suggests that teriparatide, bisphosphonates, ...

Source: Hormone and Metabolic Research - July 31, 2023 Category: Endocrinology Authors: Liang, Haodong Zhao, Jinlong Tian, Tianzhao Tags: Review Source Type: research